Annovis Bio, INC 8-K filings

Annovis Bio successfully held its 2024 Annual Meeting, electing all director nominees and approving an amendment to the equity incentive plan.

Annovis Bio's Buntanetap demonstrated statistically significant efficacy and safety in both APOE4 carriers and non-carriers in a Phase II/III Alzheimer's study.

Annovis Bio, a clinical-stage drug company, has announced an investor webcast to discuss the progress of its lead drug candidate, Buntanetap, for neurodegenerative diseases.

Annovis Bio announces the publication of a peer-reviewed article detailing the pharmacokinetic profile of Posiphen across multiple species, including humans.

Annovis Bio reported positive Phase II/III Alzheimer's data and provided a corporate update, including financial results for the first quarter of 2024.

Annovis Bio has completed data cleaning for its Phase III Parkinson's disease study of buntanetap, with topline efficacy data expected in June following a two-month delay.

Annovis Bio's CEO issued a letter to stockholders addressing concerns and outlining next steps following the Phase II/III Alzheimer's study results.

Annovis Bio, Inc. has finalized a common stock purchase agreement, issuing shares to an equity line investor.

Annovis Bio, Inc. has announced the departure of its Chief Financial Officer, Henry Hagopian, effective April 30, 2024, and the appointment of CEO Maria Maccecchini as interim CFO.

Annovis Bio has entered into a common stock purchase agreement with an equity line investor, potentially raising up to $20 million for working capital and general corporate purposes.

Annovis Bio announced its fourth quarter and full year 2023 financial results, along with updates on its Phase III Parkinson's Disease and Phase II/III Alzheimer's Disease clinical trials.

Annovis Bio, Inc. successfully closed a stock offering, raising $3 million in gross proceeds.

Annovis Bio, Inc. has entered into a securities purchase agreement to sell 316,455 shares of common stock at $9.48 per share, raising $3 million in gross proceeds.

Annovis Bio has successfully completed data cleaning for its Phase II/III study of buntanetap in Alzheimer's disease, with topline efficacy data anticipated in April.

Annovis Bio, Inc. successfully closed a share offering, raising $1.025 million in gross proceeds.

Annovis Bio, Inc. has entered into a securities purchase agreement to sell 114,911 shares of common stock at $8.92 per share, raising gross proceeds of $1.025 million.